Recombinant Hepatitis E vaccine Market Size, Share & Revenue Outlook 2032 According to a newly published market research report by 24LifeSciences, global recombinant Hepatitis E vaccine market was valued at USD 165.7 million in 2024 and is projected to reach USD 289.4 million by 2032, growing at a compound annual growth rate (CAGR) of 7.2% during the forecast period 20252032. Recombinant Hepatitis E vaccines are biologically engineered immunizations that protect against Hepatitis E virus (HEV) infection by stimulating an immune response to viral antigens. These vaccines utilize recombinant DNA technology to produce antigenic proteins identical to those found in HEV, providing targeted immunity. Their established efficacy in preventing hepatitis E infections continues to underpin their importance in public health initiatives, particularly in endemic regions and among high-risk populations. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/14004/recombinant-hepatitis-e-vaccine-market